单菌多次级代谢产物方法及其在微生物代谢产物研究中的应用

微生物次级代谢产物的结构多样性赋予其广泛的生物活性,是药物先导化合物的重要来源。然而传统单一的培养方法,使微生物中大量的代谢途径不能被表达,以至于许多代谢产物不能产生。因此,运用各种技术和方法激活这些沉默途径,获得结构多样的代谢产物已成为目前关注的热点。单菌多次级代谢产物(Onestrainmany compounds,OSMAC)策略作为一种简便有效的研究手段,已成功应用于该领域的研究。本文综述了OSMAC策略中常用的研究手段(包括改变培养状态、混合培养及添加酶抑制剂等),以及OSMAC与基因组扫描技术相结合的研究进展,并介绍了本研究室利用此方法对高产细胞松弛素的海洋来源真菌曲丽穗霉(Spicaria elegans KLA03)进行研究的部分结果。     

隐性次级代谢产物生物合成基因簇的激活及天然产物定向发现

传统的"活性-化合物"天然药物发现方法导致大量已知化合物被重复分离,大大加剧了新药发现的难度。规模化基因组测序揭示了微生物基因组中存在大量的隐性(cryptic)次级代谢产物生物合成基因簇,如何激活这些隐性基因簇成为当今世界天然产物研究领域的难点与热点。本文从途径特异性和多效性两个角度综述了隐性生物合成基因簇激活策略;同时,对基因组信息指导下结构导向(structure-guided)的化合物定向分离技术进行了归纳。隐性基因簇的激活为定向发掘具有优良活性的新型天然产物提供了新的契机。     

海洋动物来源微生物的共培养研究进展

近年来,由于一些新疾病的发生和细菌耐药性的出现,微生物来源次级代谢产物的筛选重复率越来越高,微生物一些代谢基因在现有实验室条件下无法表达,所以需要发现新的微生物资源,同时找到激活微生物代谢产物基因的方法。海洋动物体内蕴含着大量的共附生微生物资源,可以产生很多具有生物活性的化合物,是潜在的药用资源。本文综述了近年来海洋动物(海鞘、海绵、珊瑚和海葵等)来源的微生物进行共培养的研究策略,包括共培养菌株的选择、共培养条件、群体感应和信号分子对共培养菌株的影响,以及不同种类微生物间的共培养实例。共培养与单培养相比,增加了次级代谢产物的种类,提高了次级代谢产物的生物活性或产量。共培养的研究有助于发现新的海洋动物来源微生物的活性天然产物,为海洋药物的开发提供新思路。     

构建高质量微生物天然产物库研究策略

微生物次级代谢产物历来是天然药物的重要来源,过去曾被称为"生物沙漠"的海洋,由于从中分离到大量新的微生物、基因及生物活性化合物,被重新认识逆转而成为一种"生物多样化的热带雨林".构建一个高质量微生物库及其天然产物库是保证药物和其他筛选成功的前提和关键.但如何高效建立高质量微生物天然产物库仍面临很多瓶颈问题.我们拟从:(1)扩大可培养微生物的多样性及去重复化;(2)扩大基因资源多样性及去重复化;(3)扩大微生物次级代谢产物多样性及去重复化;(4)寻找崭新次级代谢产物的新技术新方法,特别是针对多靶位药物的高通量互动筛选方面提出应对的研究策略.利用上述化学微生物学策略分离生物活性化合物不仅在生物技术和制药学应用中显现重要性,也增加了我们对微生物的多样性、生态系统功能和应用生物学的理解.     

微生物代谢产物在溶栓药物制备中的应用研究进展

目的 :探讨从微生物代谢产物中寻找溶栓药物制备的研究方法和动态。方法 :从大量的近期文献中阐述了来源于微生物代谢产物溶栓药物的性质和优缺点。结果 :从微生物代谢产物中寻找溶栓药物是传统而又简单的方法 ,比较经济实惠。结论 :微生物代谢产物是溶栓药物或其他药物的重要来源。     

微生物共培养研究进展

微生物是天然先导药物的重要来源之一。鉴于微生物间的自然相互作用、模拟微生物种群间营养和空间竞争是诱导产生活性次生代谢产物的主要途径,微生物共培养已经成为提高生产效价和发现新化合物的重要方法,是工业、农业、医药、食品及环保等领域的热点问题。本文综述了国内外关于微生物共培养的研究报道,包括微生物之间生态学关系、共培养微生物产生的活性次生代谢产物、微生物共培养的应用等。共培养能丰富微生物化学多样性,是应用微生物学和天然产物化学研究的新方向。     

海洋来源节菱孢菌ZSDS1-F3中PKS-NRPS类天然产物挖掘

【目的】以基因组信息为指导,定向激活海洋来源真菌Arthrinium arundinisZSDS1-F3中沉默的聚酮合成酶-非核糖体肽合成酶(PKS-NRPS)类生物合成基因簇,鉴定次级代谢产物结构。【方法】通过启动子工程和异源表达的策略激活实验室培养条件下沉默或低表达的生物合成基因簇,实现目标化合物的分离,通过HR-ESI-MS和NMR数据分析鉴定产物结构,结合基因重组和生物信息学分析结果推导化合物的生物合成途径。【结果】依据基因组生物信息学分析,从海洋来源真菌A. arundinis ZSDS1-F3中选取一个编码PKS-NRPS类次级代谢产物的生物合成基因簇开展研究,在宿主Aspergillus nidulansA1145中实现了基因簇的异源表达,从中分离到2个新化合物,并推导了其生物合成途径。【结论】基因组信息指导下的天然产物挖掘,可以目标明确地分离产物,加快真菌中新颖天然产物的发现步伐。     

连续流生物反应器技术在微生物培养中的应用

自然环境中99%微生物在实验室条件下仍是不能被培养的,称之为"未培养"微生物或微生物"暗物质"。对其进行研究不仅有助于认识环境中微生物代谢多样性,丰富生命之树,同时未培养微生物还蕴含着巨大的新基因和新天然产物资源。但传统培养技术的局限性阻碍了"未培养"微生物资源的开发和利用。虽然随着分子生物学技术的发展,可以直接从环境中获得未培养微生物的遗传信息,分析微生物的广泛代谢多样性,但微生物的生理特征和代谢产物等分析仍然需要建立在研究纯菌株的基础上。目前,已经有很多新颖的培养技术被研发,如原位培养技术、共培养技术和连续流生物反应器培养技术等用于挖掘未培养微生物资源。本文主要介绍了连续流生物反应器培养新技术的发展与改进,探讨了"未培养"微生物培养技术及设备的发展方向,以进一步促进"未培养"微生物资源的开发与利用。     

基于微生物共培养的隐性基因簇激活策略

微生物次级代谢产物是药物先导化合物的重要源泉之一。随着测序技术的迅猛发展,越来越多的微生物基因组得以测序完成。伴随着测序技术的进步,生物信息学也得到了快速发展。基因组序列分析发现,链霉菌和丝状真菌等微生物中存在大量的已知的或未知的次级代谢物生物合成基因簇(secondary metabolite-biosynthetic gene clusters,SM-BGCs)。然而,在实验室培养条件下大部分基因簇无法表达或表达量很低,导致难以发现这些基因簇所对应的代谢产物,人们将这类基因簇称为“隐性基因簇”或“沉默基因簇”。通过调节基因簇中特异调控基因或基因簇外全局性调控基因的表达,对代谢途径的定向改造,以及将基因簇导入异源宿主等策略,能够激活部分隐性基因簇的表达。通过激活隐性基因簇的表达,能够发现通过常规实验室培养无法获得的具有独特生物活性的新结构代谢产物,成为创新药物的重要来源之一。然而,这些基因簇激活策略都严重依赖于对特定菌株或宿主的遗传操作。近年来,通过模拟自然混合培养中微生物间相互作用,开发了通过混合特定微生物菌株在厌氧或好氧条件下激活隐性基因簇的方法,称之为共培养激活策略。这种策略不依赖于基因组信息,也不依赖于对特定菌株或宿主的遗传操作技术,具有操作简单和方便的优点。共培养策略需要混合培养的不同微生物具有相似的生长速度以及不能够产生拮抗等要求,因而也部分限制了该策略的应用。近期合成微生物组学的出现有可能改变这一限制,使共培养策略得到更加广泛的应用。本文围绕微生物共培养体系和应用、基于共培养策略的产物挖掘以及可能的激活机制等进行了综述。     

地衣型真菌石果衣(疣孢菌科，子囊菌门)次级代谢产物的多样性

地衣能够产生大量的新型次级代谢产物,但以往对石果衣Endocarpon pusillum的研究中未能检测出任何次级代谢产物。然而,对其共生菌进行基因组测序发现其中含有14个沉默的PKS基因和2个沉默的NRPS基因。在此研究中,为激活其途径,使用了优化马铃薯培养基和大米培养基对石果衣共生真菌进行了培养。从优化马铃薯培养物中分离得到9个次级代谢产物,包括2个新的异吲哚-1-酮类化合物(1, 2)。而从大米培养物中分离到3个已知化合物和1个新的萘醌类化合物(9)。通过核磁共振和质谱数据确定了新化合物的结构。研究结果表明,大量地衣中未能检测出任何次级代谢产物,或仅能检测出少量次级代谢产物,可能与其基因组中的沉默基因有关。因此,通过对沉默基因的激活方法为地衣次级代谢产物资源的研究与开发开辟了有效途径。     

Exploring anti-TB leads from natural products library originated from marine microbes and medicinal plants

Multidrug-resistant tuberculosis (MDR-TB) and TB–HIV co-infection have become a great threat to global health. However, the last truly novel drug that was approved for the treatment of TB was discovered 40?years ago. The search for new effective drugs against TB has never been more intensive. Natural products derived from microbes and medicinal plants have been an important source of TB therapeutics. Recent advances have been made to accelerate the discovery rate of novel TB drugs including diversifying strategies for environmental strains, high-throughput screening (HTS) assays, and chemical diversity. This review will discuss the challenges of finding novel natural products with anti-TB activity from marine microbes and plant medicines, including biodiversity- and taxonomy-guided microbial natural products library construction, target- and cell-based HTS, and bioassay-directed isolation of anti-TB substances from traditional medicines.     

2D-QSAR model development and analysis on variant groups of anti-tuberculosis drugs

A quantitative structure activity relationship study was performed on different groups of anti-tuberculosis drug compound for establishing quantitative relationship between biological activity and their physicochemical /structural properties. In recent years, a large number of herbal drugs are promoted in treatment of tuberculosis especially due to the emergence of MDR (multi drug resistance) and XDR (extensive drug resistance) tuberculosis. Multidrug-resistant TB (MDR-TB) is resistant to front-line drugs (isoniazid and rifampicin, the most powerful anti-TB drugs) and extensively drug-resistant TB (XDR-TB) is resistant to front-line and second-line drugs. The possibility of drug resistance TB increases when patient does not take prescribed drugs for defined time period. Natural products (secondary metabolites) isolated from the variety of sources including terrestrial and marine plants and animals, and microorganisms, have been recognized as having antituberculosis action and have recently been tested preclinically for their growth inhibitory activity towards Mycobacterium tuberculosis or related organisms. A quantitative structure activity relationship (QSAR) studies were performed to explore the antituberculosis compound from the derivatives of natural products . Theoretical results are in accord with the in vitro experimental data with reported growth inhibitory activity towards Mycobacterium tuberculosis or related organisms. Antitubercular activity was predicted through QSAR model, developed by forward feed multiple linear regression method with leave-one-out approach. Relationship correlating measure of QSAR model was 74% (R(2) = 0.74) and predictive accuracy was 72% (RCV(2) = 0.72). QSAR studies indicate that dipole energy and heat of formation correlate well with anti-tubercular activity. These results could offer useful references for understanding mechanisms and directing the molecular design of new lead compounds with improved anti-tubercular activity. The generated QSAR model revealed the importance of structural, thermodynamic and electro topological parameters. The quantitative structure activity relationship provides important structural insight in designing of potent antitubercular agent.     

New perspectives on natural products in TB drug research

The challenge of discovering new, urgently needed anti-TB drugs from natural sources requires a truly interdisciplinary research. Cutting-edge mycobacteriology and innovative natural products chemistry tools have to be developed and employed in tandem, in order to meet these demands. The present review provides cross-linkage to the most recent literature on anti-TB active natural products and summarizes the recent developments in both fields and their potential to impact the early steps of the TB drug discovery process.     

非一线抗结核药物耐药机制及耐药性诊断研究进展

结核病(Tuberculosis, TB)至今仍是世界三大传染疾病之一。2014年,TB导致的死亡人数已经超过HIV。二线抗TB药物是临床治疗耐多药TB(Multidrug-resistant TB, MDR-TB)的主要药物,然而某些MDR-TB患者由于未及时诊断、治疗方案不合理、所处区域医疗条件差等原因,逐渐发展成为广泛耐药TB(Extensively drug-resistant TB, XDR-TB),使治疗更加困难,其死亡率甚至与肺癌接近。目前结核分枝杆菌(Mycobacterium tuberculosis)的耐药性机制研究已经转向非一线药物,如二线、三线和一些新研发的抗TB药物,揭示这些非一线药物的耐药机制对于耐药TB的治疗和新型抗TB药物的研发具有重要意义。本文对目前临床上使用的主要非一线药物的耐药机制研究进行了综述,并对目前常用的TB耐药性诊断方法的优缺点进行了归纳比较。     

Drug resistance mechanisms and novel drug targets for tuberculosis therapy

Drug-resistant tuberculosis (TB) poses a significant challenge to the successful treatment and control of TB worldwide. Resistance to anti-TB drugs has existed since the beginning of the chemotherapy era. New insights into the resistant mechanisms of anti-TB drugs have been provided. Better understanding of drug resistance mechanisms helps in the development of new tools for the rapid diagnosis of drug-resistant TB. There is also a pressing need in the development of new drugs with novel targets to improve the current treatment of TB and to prevent the emergence of drug resistance in Mycobacterium tuberculosis. This review summarizes the anti-TB drug resistance mechanisms, furnishes some possible novel drug targets in the development of new agents for TB therapy and discusses the usefulness using known targets to develop new anti-TB drugs. Whole genome sequencing is currently an advanced technology to uncover drug resistance mechanisms in M. tuberculosis. However, further research is required to unravel the significance of some newly discovered gene mutations in their contribution to drug resistance.     

Host-Directed Therapeutics for Tuberculosis: Can We Harness the Host?

SUMMARY

Treatment of tuberculosis (TB) remains challenging, with lengthy treatment durations and complex drug regimens that are toxic and difficult to administer. Similar to the vast majority of antibiotics, drugs for Mycobacterium tuberculosis are directed against microbial targets. Although more effective drugs that target the bacterium may lead to faster cure of patients, it is possible that a biological limit will be reached that can be overcome only by adopting a fundamentally new treatment approach. TB regimens might be improved by including agents that target host pathways. Recent work on host-pathogen interactions, host immunity, and host-directed interventions suggests that supplementing anti-TB therapy with host modulators may lead to shorter treatment times, a reduction in lung damage caused by the disease, and a lower risk of relapse or reinfection. We undertook this review to identify molecular pathways of the host that may be amenable to modulation by small molecules for the treatment of TB. Although several approaches to augmenting standard TB treatment have been proposed, only a few have been explored in detail or advanced to preclinical and clinical studies. Our review focuses on molecular targets and inhibitory small molecules that function within the macrophage or other myeloid cells, on host inflammatory pathways, or at the level of TB-induced lung pathology.     

Mycobacterium tuberculosis cytochrome P450 enzymes: a cohort of novel TB drug targets

TB (tuberculosis) disease remains responsible for the death of over 1.5 million people each year. The alarming emergence of drug-resistant TB has sparked a critical need for new front-line TB drugs with a novel mode of action. In the present paper, we review recent genomic and biochemical evidence implicating Mycobacterium tuberculosis CYP (cytochrome P450) enzymes as exciting potential targets for new classes of anti-tuberculars. We also discuss HTS (high-throughput screening) and fragment-based drug-discovery campaigns that are being used to probe their potential druggability.     

A review on anti‐tuberculosis peptides: Impact of peptide structure on anti‐tuberculosis activity

Antibiotic resistance is a major public health problem globally. Particularly concerning amongst drug‐resistant human pathogens is Mycobacterium tuberculosis that causes the deadly infectious tuberculosis (TB) disease. Significant issues associated with current treatment options for drug‐resistant TB and the high rate of mortality from the disease makes the development of novel treatment options against this pathogen an urgent need. Antimicrobial peptides are part of innate immunity in all forms of life and could provide a potential solution against drug‐resistant TB. This review is a critical analysis of antimicrobial peptides that are reported to be active against the M tuberculosis complex exclusively. However, activity on non‐TB strains such as Mycobacterium avium and Mycobacterium intracellulare, whenever available, have been included at appropriate sections for these anti‐TB peptides. Natural and synthetic antimicrobial peptides of diverse sequences, along with their chemical structures, are presented, discussed, and correlated to their observed antimycobacterial activities. Critical analyses of the structure allied to the anti‐mycobacterial activity have allowed us to draw important conclusions and ideas for research and development on these promising molecules to realise their full potential. Even though the review is focussed on peptides, we have briefly summarised the structures and potency of the various small molecule drugs that are available and under development, for TB treatment.